Shares of Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) have been given a consensus broker rating score of 1.50 (Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a buy recommendation and one has given a strong buy recommendation to the company.
Brokerages have set a 1-year consensus target price of $19.00 for the company and are forecasting that the company will post $0.20 EPS for the current quarter, according to Zacks. Zacks has also assigned Osmotica Pharmaceuticals an industry rank of 51 out of 256 based on the ratings given to related companies.
A number of equities analysts have recently commented on the stock. Barclays assumed coverage on shares of Osmotica Pharmaceuticals in a research report on Wednesday, November 14th. They issued an “overweight” rating for the company. Jefferies Financial Group started coverage on shares of Osmotica Pharmaceuticals in a research report on Monday, November 12th. They issued a “buy” rating for the company. Wells Fargo & Co started coverage on shares of Osmotica Pharmaceuticals in a research note on Monday, November 12th. They issued an “outperform” rating and a $18.00 target price on the stock. Finally, Royal Bank of Canada started coverage on shares of Osmotica Pharmaceuticals in a research note on Monday, November 12th. They issued an “outperform” rating and a $17.00 target price on the stock.
OSMT stock opened at $8.31 on Friday. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.29 and a quick ratio of 1.07. Osmotica Pharmaceuticals has a 12 month low of $6.21 and a 12 month high of $9.90.
Osmotica Pharmaceuticals (NASDAQ:OSMT) last released its quarterly earnings data on Thursday, November 8th. The company reported ($4.99) EPS for the quarter. The firm had revenue of $66.35 million for the quarter. As a group, research analysts anticipate that Osmotica Pharmaceuticals will post 4.31 EPS for the current year.
About Osmotica Pharmaceuticals
Osmotica Pharmaceuticals Plc is a holding company engages in the development and commercialization of specialty products that target markets with underserved patient populations. It offers the M-72, Lorzone which is the chlorzoxazone scored tablets and ConZip which is tramadol hydrochloride extended-release capsules in specialty neurology; and OB Complete, which is the family of prescription prenatal dietary supplements, and Divigel in women’s health.
Recommended Story: What is the S&P 500 Index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.